Placebo News and Research

RSS

RNA interference agent plozasiran targets APOC3 for effective mixed hyperlipidemia treatment

Researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia.

31 May 2024

Wake Forest researchers to study bone health post-bariatric surgery with $1.5 million NIH grant

Researchers at Wake Forest University of School of Medicine have received a five-year, $1.5 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, to study bone microarchitecture in patients following bariatric surgery.

30 May 2024

Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.

30 May 2024

RNA-based therapy shows promise in reducing cholesterol and triglycerides

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

29 May 2024

Psychoactive drugs are having a moment. The FDA will soon weigh in.

Lori Tipton is among the growing number of people who say that MDMA, also known as ecstasy, saved their lives.

29 May 2024

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.

29 May 2024

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial

A recent study in Nature Medicine found that LM11A-31, targeting the p75 neurotrophin receptor, is safe and shows promise in slowing Alzheimer's disease progression. The trial indicated significant biomarker improvements and potential benefits for further clinical investigation.

28 May 2024

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight semaglutide's benefits for kidney function and overall cardiovascular health.

28 May 2024

Light therapy may affect healing in the brains of people who suffered traumatic brain injury

Low-level light therapy appears to affect healing in the brains of people who suffered significant brain injuries, according to a study published today in Radiology, a journal of the Radiological Society of North America.

28 May 2024

Taking semaglutide once weekly may lower the chances of kidney disease, says study

The effects of semaglutide (administered once weekly) on the outcomes of kidney disease.

28 May 2024

New antibody therapy shows promise in combating kidney transplant rejection

Antibody-mediated rejection (AMR) is one of the most common causes of kidney transplant failure. To date, however, no treatment has proven effective in combating this complication in the long term.

27 May 2024

SELECT trial shows semaglutide reduces kidney decline in obese patients

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.

25 May 2024

Psilocybin use initiates hyperconnectivity in the brain linked to ego-modifying effects

A new study shows that the use of psilocybin, a compound found in the widely known "magic mushrooms," initiates a pattern of hyperconnectivity in the brain linked to the ego-modifying effects and feelings of oceanic boundlessness.

23 May 2024

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Dupilumab significantly reduces exacerbations and improves lung function in COPD patients with elevated eosinophil counts, confirming the efficacy of targeting type 2 inflammation.

22 May 2024

100-year-old BCG vaccine protects individuals with type 1 diabetes from infectious diseases

In new research, investigators at Massachusetts General Hospital (MGH) show that the 100-year-old Bacillus Calmette-Guérin (BCG) vaccine, originally developed to prevent tuberculosis, protects individuals with type 1 diabetes from severe COVID-19 disease and other infectious diseases.

22 May 2024

Lemon verbena extract boosts sleep quality

Researchers explore the utility of lemon verbena in improving the sleep of individuals with poor sleep.

22 May 2024

4 ways vaccine skeptics mislead you on measles and more

Measles is on the rise in the United States. So far this year, the number of cases is about 17 times what it was, on average, during the same period in each of the four years before, according to the Centers for Disease Control and Prevention.

22 May 2024

Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results

Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.

20 May 2024

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.

20 May 2024

SIDBI trial: No benefit of iron supplements for breastfed infants' development

The American Pediatric Association recommends iron supplements to all healthy infants who breastfeed longer than 4 months, while its European counterpart, Society of Gastroenterology, Hepataology and Nutrition, does not recommend it.

20 May 2024

Placebo News and Research

RNA interference agent plozasiran targets APOC3 for effective mixed hyperlipidemia treatment

Wake Forest researchers to study bone health post-bariatric surgery with $1.5 million NIH grant

Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

RNA-based therapy shows promise in reducing cholesterol and triglycerides

Psychoactive drugs are having a moment. The FDA will soon weigh in.

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Light therapy may affect healing in the brains of people who suffered traumatic brain injury

Taking semaglutide once weekly may lower the chances of kidney disease, says study

New antibody therapy shows promise in combating kidney transplant rejection

SELECT trial shows semaglutide reduces kidney decline in obese patients

Psilocybin use initiates hyperconnectivity in the brain linked to ego-modifying effects

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

100-year-old BCG vaccine protects individuals with type 1 diabetes from infectious diseases

Lemon verbena extract boosts sleep quality

4 ways vaccine skeptics mislead you on measles and more

Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

SIDBI trial: No benefit of iron supplements for breastfed infants' development

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News